Bleeding events of direct oral anti-coagulant for treatment of venous thromboembolism in advanced cancer patients.

Bleeding events of direct oral anti-coagulant for treatment of venous thromboembolism in advanced cancer patients. - Bleeding events of direct oral anti-coagulant for treatment of venous thromboembolism in advanced cancer patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020275

Enrollment

147

Registered

2015-12-19

Start date

2015-12-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmation of cancer. 2)Advanced cancer patients. 3)Deep venous thrombosis and/or plumonary embolism. 4)Thrombus documented by contrast enhanced CT or ultrasonography. 5)Direct oral anti-coagulant is planned. 6)Written informed consent.

Exclusion criteria

Exclusion criteria: 1)Other anti-coagulant or anti-platelet is administered. 2)Other disease requiring anti-coagulant therapy. 3)History of intracranial bleeding. 4)Active bleeding. 5)Thrombolytic therapy is planned. 6)Renal failure (Cre>=1.5mg/dL) 7)Platelet count <100,000/mm3

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the incidence of bleeding during the 12 weeks of treatment of venous thromboembolism with direct oral anti-coagulant.	—

Secondary

Measure	Time frame
The secondary endpoint is the incidence of adverse events during the 12 weeks of treatment of thromboembolism with direct oral anti-coagulant.	—

Countries

Japan

Contacts

Public ContactTakuya Oyakawa

Shizuoka Cancer Center Cardiology

t.oyakawa@scchr.jp(+81)055-989-5222

Outcome results